IVERIC bio, Inc. clinical trials
Acquired by Astellas Pharma Inc, Jul 11, 2023 · source ↗
The registry lists 3 studies whose lead sponsor is IVERIC bio, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2025.
Before and after it joined Astellas Pharma Inc
- First submitted before IVERIC bio, Inc. became part of Astellas Pharma Inc
- 3
- First submitted after IVERIC bio, Inc. became part of Astellas Pharma Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- IVERIC bio, Inc.3 studies
Something wrong with this grouping? Tell us on the Astellas Pharma Inc page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Astellas Pharma Inc studies →
- A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)CompletedNCT04435366Phase 3
Sponsor listed in the registry: IVERIC bio, Inc. · First submitted before IVERIC bio, Inc. became part of Astellas Pharma Inc
- Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationCompletedNCT02686658Phase 2/3
Sponsor listed in the registry: IVERIC bio, Inc. · First submitted before IVERIC bio, Inc. became part of Astellas Pharma Inc
- Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMDTerminatedNCT05571267Phase 2
Sponsor listed in the registry: IVERIC bio, Inc. · First submitted before IVERIC bio, Inc. became part of Astellas Pharma Inc